Skip to main content

Table 2 Antipsychotic, and non-antipsychotic medication taken by patients with SMI

From: A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients

Drug n (%)
Antipsychotic (n = 90)  
Yes 83 (92.2)
No 7 (7.8)
One antipsychotic 71 (78.8)
Combination antipsychotic 12 (13.3)
Typical or atypical agent (n = 71)  
   Typical 16 (22.5)
Zuclopenthixol 2 (2.8)
Flupenthixol 5 (7.0)
Haloperidol 1 (1.4)
Fluphenazine 1 (1.4)
Pipothiazine 1 (1.4)
Sulpiride 4 (5.6)
Trifluoperazine 2 (2.8)
   Atypical 55 (77.5)
Amisulpiride 3 (4.2)
Clozapine 7 (9.9)
Olanzapine 29 (40.8)
Quetiapine 8 (11.3)
Risperidone 8 (11.3)
Non-antipsychotic psychotropic drugs (n = 90)  
   Antidepressants  
SSRI 29 (32.2)
SNRI 9 (10)
NaSSA 4 (4.4)
TCA 7 (7.8)
MAOI 3 (3.3)
   Mood Stabiliser  
Valproate 16 (17.8)
Lamotrigine 8 (8.9)
Carbamazepine 1 (1.1)
Lithium 15 (16.7)
   Other  
Gabapentin 2 (2.2)
Benzodiazepines 28 (31.1)
Tryptophan 2 (2.2)
Anticholinergic agent 15 (16.7)
Non-psychotropic drugs (n = 90)  
Antihypertensive agent 13 (14.4)
Thyroxine 10 (11.1)
Hypoglycaemic agent 4 (4.4)